Page 22 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Progress in the research of pathology and therapy in liver fibrosis

enzyme PCK1 promotes metabolic-associated fatty liver and biomarkers in alcohol-related liver disease. J Hepatol.
disease through PI3K/AKT/PDGF axis activation in male 2019;70(2):273-283.
mice. Nat Commun. 2023;14(1):1402.
doi: 10.1016/j.jhep.2018.11.025
doi: 10.1038/s41467-023-37142-3 44. Hagström H, Talbäck M, Andreasson A, Walldius G,
33. Kostallari E, Hirsova P, Prasnicka A, et al. Hepatic stellate Hammar N. Repeated FIB-4 measurements can help
cell-derived platelet-derived growth factor receptor-alpha- identify individuals at risk of severe liver disease. J Hepatol.
enriched extracellular vesicles promote liver fibrosis in mice 2020;73(5):1023-1029.
through SHP2. Hepatology. 2018;68(1):333-348.
doi: 10.1016/j.jhep.2020.06.007
doi: 10.1002/hep.29803
45. Roccarina D, Iogna Prat L, Pallini G, et al. Comparison of
34. Wang F, Chen L, Kong D, et al. Canonical Wnt signaling point-shear wave elastography (ElastPQ) and transient
promotes HSC glycolysis and liver fibrosis through an elastography (FibroScan) for liver fibrosis staging in
LDH-A/HIF-1alpha transcriptional complex. Hepatology. patients with non-alcoholic fatty liver disease. Liver Int.
2024;79(3):606-623. 2022;42(10):2195-2203.
doi: 10.1097/HEP.0000000000000569 doi: 10.1111/liv.15297
35. Hu Y, Peng L, Zhuo X, Yang C, Zhang Y. Hedgehog signaling 46. Serra-Burriel M, Graupera I, Torán P, et al. Transient
pathway in fibrosis and targeted therapies. Biomolecules. elastography for screening of liver fibrosis: Cost-effectiveness
2024;14(12):1485. analysis from six prospective cohorts in Europe and Asia.
J Hepatol. 2019;71(6):1141-1151.
doi: 10.3390/biom14121485
doi: 10.1016/j.jhep.2019.08.019
36. Lo RC, Kim H. Histopathological evaluation of liver fibrosis
and cirrhosis regression. Clin Mol Hepatol. 2017;23(4):302-307. 47. Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ.
Current and emerging biomarkers and imaging modalities
doi: 10.3350/cmh.2017.0078
for nonalcoholic fatty liver disease: Clinical and research
37. Colling R, Verrill C, Fryer E, et al. Bile duct basement applications. Clin Ther. 2021;43(9):1505-1522.
membrane thickening in primary sclerosing cholangitis. doi: 10.1016/j.clinthera.2021.07.012
Histopathology. 2016;68(6):819-824.
48. Wu L, Huang X-Q, Li N, et al. A magnetic resonance imaging
doi: 10.1111/his.12857
modality for non-invasively distinguishing progression of
38. Bedossa P, Poynard T. An algorithm for the grading of liver fibrosis by visualizing hepatic platelet-derived growth
activity in chronic hepatitis C. The METAVIR Cooperative factor receptor-beta expression in mice. J Gastroenterol
Study Group. Hepatology. 1996;24(2):289-293. Hepatol. 2021;36(12):3448-3456.
doi: 10.1002/hep.510240201 doi: 10.1111/jgh.15628
39. Ishak K, Baptista A, Bianchi L, et al. Histological grading and 49. Hsu C, Caussy C, Imajo K, et al. Magnetic Resonance
staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699. vs Transient Elastography analysis of patients with
nonalcoholic fatty liver disease: A systematic review and
doi: 10.1016/0168-8278(95)80226-6
pooled analysis of individual participants. Clin Gastroenterol
40. Chowdhury AB, Mehta KJ. Liver biopsy for assessment Hepatol. 2019;17(4):630-637.e8.
of chronic liver diseases: A synopsis. Clin Exp Med.
2023;23:273-285. doi: 10.1016/j.cgh.2018.05.059
50. Coste P, Llop E, Perelló C, et al. Comparison of non-invasive
doi: 10.1007/s10238-022-00799-z
fibrosis scores to predict increased liver stiffness in the
41. Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive general population with unknown liver disease: Searching
markers of liver fibrosis: Adjuncts or alternatives to liver for the primary physician’s best friend. Dig Liver Dis.
biopsy? Front Pharmacol. 2016;7:159. 2022;54(9):1209-1214.
doi: 10.3389/fphar.2016.00159 doi: 10.1016/j.dld.2022.03.013
42. Younossi ZM, Noureddin M, Bernstein D, et al. Role of 51. Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison
noninvasive tests in clinical gastroenterology practices to between MEFIB, MAST, and FAST for detecting stage 2
identify patients with nonalcoholic steatohepatitis at high fibrosis or higher among patients with NAFLD. J Hepatol.
risk of adverse outcomes: Expert panel recommendations. 2022;77(6):1482-1490.
Am J Gastroenterol. 2021;116(2):254-262.
doi: 10.1016/j.jhep.2022.07.020
doi: 10.14309/ajg.0000000000001054
52. Long MT, Noureddin M, Lim JK. AGA clinical practice
43. Moreno C, Mueller S, Szabo G. Non-invasive diagnosis update: Diagnosis and management of nonalcoholic

Volume 9 Issue 3 (2025) 14 doi: 10.36922/ejmo.8125